Slough Estates PLC
Pfizer Buys Life Sciences Campus from Slough Estates for $372 Million
Slough Estates plc, a leading provider of flexible business space, today
announced that Pfizer has purchased their Global Research and Development Center
in San Diego from Slough Estates for $372 million. The master-planned campus,
developed by Slough Estates USA Inc, is situated on a prominent site in the
prestigious Torrey Pines life sciences market area. Following the disposal,
Slough will continue to own about 700,000 square feet of life sciences product
in the area and an additional 80 acres of development land in San Diego County.
The Pfizer campus includes eight buildings totalling 770,000 square feet. The
half-year valuation of $275 million compared very favourably to the total
development cost of $175 million. Slough constructed the project over a
five-year period commencing with Agouron Pharmaceuticals in 1999, which
subsequently became a subsidiary of Warner-Lambert. In 2000, following the
acquisition of Warner-Lambert by Pfizer, the campus was expanded significantly.
The proceeds from this sale and other selective dispositions will primarily be
redeployed in Slough's life sciences business in California as part of the
broader strategic objective to reinforce Slough Estates USA Inc. as a
self-financing part of the Group.
Ian Coull, Chief Executive of Slough Estates commented: 'The acquisition of its
Global Research and Development Center by Pfizer reflects the quality of our
projects in California and validates the success that we have achieved in life
sciences facilities development by working closely with our customers to deliver
a market leading product. The transaction also evidences the attractive
financial returns that Slough has achieved in the provision of laboratory space
to the rapidly-growing life sciences industry. The sale price and profit
achieved confirm and support our positive view of the valuation of the entire
Slough life sciences portfolio.'
UBS acted as sole financial advisor to Slough Estates on this transaction.
For further information contact:
Slough Estates plc Shared Value Limited
Ian Coull, Chief Executive Andrew Best / Emily Bruning
Tel: 01753 537171 Tel: 020 7321 5022 / 5027
Slough Estates is a leading provider of flexible business space in business
parks in Western Europe and North America, with over 1700 customers occupying
2.9 million square metres of business space, with a total value of £3.6 billion.
Slough Estates' properties are in suburban locations in close proximity to the
main business centres, where there is long term demand for business
accommodation to serve these key economic regions. The company's main activities
are currently based around London, Brussels, Paris, Düsseldorf, San Francisco
and San Diego and the company continues to develop new business parks with the
long term objective of building shareholder value and enhancing its reputation
for quality buildings offering excellent value to customers.
www.sloughestates.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.